Breaking News

Catalent, Pure MHC in Product Development Pact

To develop humanized version of Pure MHC’s RL21A antibody

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions and Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, have signed a product development agreement under which Catalent will develop a humanized version of Pure MHC’s RL21A antibody and engineer a cell line to express the antibody using its GPEx technology. Catalent will subsequently produce purified monoclonal antibodies to support preclinical development with humanized RL21A for the treatment of cancer.    “We are confident that our partnership with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters